TCR-T cell therapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of immune cell therapy called TCR-T that targets a specific genetic change (KRAS mutation) found in some pancreatic, colorectal, and lung cancers. If you have the right genetic markers and previous treatments haven't worked, this study may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic cancer, colorectal cancer, or lung adenocarcinoma that has not responded to or you cannot tolerate standard treatments.
- Your tumor has a specific genetic change called KRAS G12V or G12D, and you carry the HLA-A*11:01 gene marker.
- You are in generally good health (able to care for yourself and up and about more than half of your waking hours).
- You have at least one tumor that can be measured on scans.
- You are willing to use effective birth control during the study and for one year after the last treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized T cell therapy designed to target specific KRAS mutations (G12V or G12D) in people with advanced solid tumors who have no standard treatment options left. The treatment involves collecting your own immune cells, engineering them to recognize and attack cancer cells with these mutations, and then infusing them back into you.
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
This trial tests a new type of cell therapy that uses your own immune cells, specially trained to attack cancer cells with a KRAS G12V or G12D mutation. It may be an option if you have advanced solid tumors that no longer respond to standard treatments.
This trial tests a new therapy using your own immune cells, engineered to recognize and attack cancer cells. It is for people with advanced solid tumors who have no other standard treatment options.
This trial tests a new cell therapy (TCR-T) designed to target KRAS mutations in advanced cancers. It is for people whose standard treatments have stopped working.
This trial tests a personalized immune cell treatment made for people with advanced solid cancers that have not responded to standard care. It’s designed for tumors carrying a specific KRAS mutation (G12V or G12D) and for people whose immune “HLA type” matches the therapy.
Hear when a new Tumor, Solid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.